Literature DB >> 21543936

2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference.

Gavin C E Stuart1, Henry Kitchener, Monica Bacon, Andreas duBois, Michael Friedlander, Jonathan Ledermann, Christian Marth, Tate Thigpen, Edward Trimble.   

Abstract

2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer. This report provides the outcomes from the Fourth Ovarian Cancer Consensus Conference.

Entities:  

Mesh：

Year:  2011        PMID： 21543936     DOI： 10.1097/IGC.0b013e31821b2568

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN： 1048-891X            Impact factor:   3.437


  107 in total

1.  Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum.

Authors:  David M Gershenson; Charlotte C Sun; Revathy B Iyer; Anais L Malpica; John J Kavanagh; Diane C Bodurka; Kathleen Schmeler; Michael Deavers
Journal:  Gynecol Oncol       Date:  2012-03-06       Impact factor: 5.482

2.  Ovarian cancer clinical trial endpoints: Society of Gynecologic Oncology white paper.

Authors:  Thomas J Herzog; Deborah K Armstrong; Mark F Brady; Robert L Coleman; Mark H Einstein; Bradley J Monk; Robert S Mannel; J Tate Thigpen; Sharee A Umpierre; Jeannine A Villella; Ronald D Alvarez
Journal:  Gynecol Oncol       Date:  2013-11-15       Impact factor: 5.482

Review 3.  Addition of bevacizumab to chemotherapy in patients with ovarian cancer: a systematic review and meta-analysis of randomized trials.

Authors:  J Li; L Zhou; X Chen; Y Ba
Journal:  Clin Transl Oncol       Date:  2015-05-20       Impact factor: 3.405

Review 4.  The COMET Handbook: version 1.0.

Authors:  Paula R Williamson; Douglas G Altman; Heather Bagley; Karen L Barnes; Jane M Blazeby; Sara T Brookes; Mike Clarke; Elizabeth Gargon; Sarah Gorst; Nicola Harman; Jamie J Kirkham; Angus McNair; Cecilia A C Prinsen; Jochen Schmitt; Caroline B Terwee; Bridget Young
Journal:  Trials       Date:  2017-06-20       Impact factor: 2.279

Review 5.  Trial-level analysis of progression-free survival and response rate as end points of trials of first-line chemotherapy in advanced ovarian cancer.

Authors:  Giuseppe Colloca; Antonella Venturino
Journal:  Med Oncol       Date:  2017-04-08       Impact factor: 3.064

6.  Cediranib combined with chemotherapy reduces tumor dissemination and prolongs the survival of mice bearing patient-derived ovarian cancer xenografts with different responsiveness to cisplatin.

Authors:  Alessandra Decio; Marta Cesca; Francesca Bizzaro; Luca Porcu; Rossana Bettolini; Paolo Ubezio; Giulia Taraboletti; Dorina Belotti; Raffaella Giavazzi
Journal:  Clin Exp Metastasis       Date:  2015-07-17       Impact factor: 5.150

7.  Statement by the Kommission OVAR of the AGO Study Group on the Use of HIPEC (Hyperthermic Intraperitoneal Chemotherapy) to Treat Primary and Recurrent Ovarian Cancer.

Authors:  P Harter; S Mahner; F Hilpert; I Runnebaum; O Ortmann; A Mustea; J Sehouli; A du Bois; U Wagner
Journal:  Geburtshilfe Frauenheilkd       Date:  2013-03       Impact factor: 2.915

8.  Intraperitoneal chemotherapy after interval debulking surgery for advanced-stage ovarian cancer: Feasibility and outcomes at a comprehensive cancer center.

Authors:  Jennifer J Mueller; Amelia Kelly; Qin Zhou; Alexia Iasonos; Kara Long Roche; Yukio Sonoda; Roisin E O'Cearbhaill; Oliver Zivanovic; Dennis S Chi; Ginger J Gardner
Journal:  Gynecol Oncol       Date:  2016-09-28       Impact factor: 5.482

Review 9.  Development of new medical treatment for epithelial ovarian cancer recurrence.

Authors:  Rosanna Mancari; Giuseppe Cutillo; Valentina Bruno; Cristina Vincenzoni; Emanuela Mancini; Ermelinda Baiocco; Simone Bruni; Giuseppe Vocaturo; Benito Chiofalo; Enrico Vizza
Journal:  Gland Surg       Date:  2020-08

10.  Patient preferences in advanced or recurrent ovarian cancer.

Authors:  Laura J Havrilesky; Angeles Alvarez Secord; Jessie A Ehrisman; Andrew Berchuck; Fidel A Valea; Paula S Lee; Stephanie L Gaillard; Greg P Samsa; David Cella; Kevin P Weinfurt; Amy P Abernethy; Shelby D Reed
Journal:  Cancer       Date:  2014-08-04       Impact factor: 6.860
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.